Skip to main content
SpringerLink
Log in

Differences Between Interferon-α and-β Treatment for Patients with Chronic Hepatitis C Virus Infection

  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

To compare virological, biochemical, and immuneresponses to human lymphoblastoid interferon(IFN-α) and human fibroblast interferon(IFN-β) in patients with chronic hepatitis C virus(HCV) infection, 120 patients were randomly assigned to threegroups (group A, 60 patients receiving IFN-α, 6million units (MU) once a day, daily for one month andthrice weekly for five months; group B, 40 patients receiving 6 MU IFN-β once a day daily fortwo months; and group C, 20 patients receiving 3 MUIFN-β twice a day (6 MU/day) daily for two months).Serum soluble interleukin-2 receptor (sIL-2R) and interleukin-6 (IL-6) levels were measured byenzyme-linked immunosorbent assay. Patients withsustained clearance of serum HCV RNA detected bypolymerase chain reaction (PCR) at six months after IFNtreatment were defined as having complete response to IFNtreatment. A low level of HCV RNA (≤10-4copies/50 mul, measured by competitive PCR) and HCV RNAof genotype 2a were favorable factors for a completeresponse to both IFNs. Complete response in group Atreatment was strongly associated with early HCV RNAclearance, in contrast with group B. A significantlyhigher HCV RNA negativity at the second week from start of treatment was noted in group C (80.0%),compared with groups A (41.6%) and B (27.5%). sIL-2Rlevels rose in each group during IFN administration. Ingroup C, alanine aminotransferase (ALT) and IL-6 levels were remarkably elevated. These findingsindicate that timing of serum HCV RNA negativity insustained response differs between IFN-α andIFN-β administrations and that early HCV RNAclearance was induced by twice-a-day IFN-βtreatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Pe rrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL, VanThie l D, Tamburro C, Lefkowitch J, Albretch J, Meschievitz C, Ortego TJ, Gibas A, Hepatitis Interventional Therapy Group: Treatment of chronic hepatitis C with recombinantinterferon alpha. A multicenter randomized, controlled trial. N Engl J Med 321:1501-1506, 1989

    Google Scholar 

  2. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, Banks SM, Hoofnagle JH: Recombinant interferon alfa Therapy for chronic hepatitisC. A randomized, double-blind, placebo-controlled trial. N Engl J Med 321:1506-1510, 1989

    Google Scholar 

  3. Hayashi J, Ohmiya M, Kishihara Y, Tani Y, Kinukawa N, Ikematsu H, Kashiwagi S: A statistical analysis of predictive factors of Response to human lymphoblastoid interferon inpatients with chronic hepatitis C. Am J Gastroenterol 89:2151-2156, 1994

    Google Scholar 

  4. Furusyo N, Hayashi J, Ueno K, Sawayama Y, Kawakami Y, Kishihara Y, Kashiwagi S: Human lymphoblastoid interferon treatment for patients with hepatitis C virus-related cirrhosis.Clin The r 19:1352-1367, 1997

    Google Scholar 

  5. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, Shiomi S, Seki S, Kobayashi K, Otani S: Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 346:1051-1055, 1995

    Google Scholar 

  6. Hayashi J, Kishihara Y, Ueno K, Yamaji K, Kawakami Y, Furusyo N, Sawayama Y, Kashiwagi S: Age-related response to interferon alfa treatment in women vs men with chronic hepatitis C virus infection. Arch Intern Med 158:177-181, 1998

    Google Scholar 

  7. Hayashi J, Kashiwagi S: Hepatitis C virus infection in theelderly. Epidemiology, prophylaxis and optimal treatment. Drugs Aging 11:296-308, 1997

    Google Scholar 

  8. Yamaji K, Hayashi J, Kawakami Y, Furusyo N, Sawayama Y, Kishihara Y, Etoh Y, Kashiwagi S: Early cle arance and re-appearance of hepatitis C virus RNA in chronic hepatitis Cpatients treated with interferon-a. J Clin Gastroente l 26:193-199, 1998

    Google Scholar 

  9. Ampurdanes S, Olmedo E, Maluenda MD, Forns X, Lopez-Labrador FX, Costa J, Sanchez-Tapias JM, de Anta MT, Rodes J: Pe rmanent response to alpha-interferon Therapy inchronic hepatitis C is preceded by rapid cle arance of HCVRNA from serum. J Hepatol 25:827-832, 1996

    Google Scholar 

  10. Karino Y, Toyota J, Sugawara M, Higashino K, Sato T, Ohmura T, Suga T, Okuuchi Y, Matsushima T: Early loss of serum hepatitis C virus RNA can predict a sustained responseto interferon Therapy in patients with chronic hepatitis C. Am J Gastroenterol 92:61-65, 1996

    Google Scholar 

  11. Sáez-Royue la F, Porres JC, Moreno A, Castillo I, Martine z G, Galiana F, Carreno V: High doses of recombinant alphainterferonor gamma-interferon for chronic hepatitis C: Arandomized, controlled trial. Hepatology 13:327-331, 1991

    Google Scholar 

  12. Ohmiya M, Hayashi J, Furusyo N, Ueno K, Kishihara Y, Nabeshima S, Kashiwagi S: Large dose natural interferon alpha treatment for patients with chronic hepatitis C. Fukuoka ActaMed 88:380-388, 1997

    Google Scholar 

  13. Re ichard O, Fobe rg U, Fryden A, Mattsson L, Norkrans G, Sonnerborg A, Wejstal R, Yun ZB, Weiland O: High sustained response rate and cle arance of viremia in chronic hepatitis Cafter treatment with interferon-alpha 2b for 60 weeks. Hepatology 19:280-285, 1994

    Google Scholar 

  14. Hayashi J, Nakashima K, Kishihara Y, Ohmiya M, Yoshimura E, Hirata M, Kashiwagi S: Improved detection of antibodies to hepatitis C virus by the second-generation assay in patients with chronic non-A, non-B liver disease. J Infect 26:287-294,1993

    Google Scholar 

  15. Hayashi J, Yoshimura E, Kishihara Y, Yamaji K, Etoh Y, Ikematsu H, Kashiwagi S: Hepatitis C virus RNA levels determined by branched DNA probe assay correlated with levelsassessed using competitive PCR. Am J Gastroenterol 91:314-318, 1996

    Google Scholar 

  16. Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, Tanaka T, Sato K, Tsuda F, Miyakawa Y, Mayumi Y: Typing hepatitis C virus by polymerase chain reaction with type-specific primers: Application to clinical surveys and tracing infectious sources. J Gen Virol 73:673-679, 1992

    Google Scholar 

  17. Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, Brechot C, Brouwer JT, Chan SW, Chayama K, Chen DS, Choo QL, Colombo M, Cuypers HTM, Date T, Dushe iko GM, Esteban JI, Fay O, Hadzyannis SJ, Han J, Hatzakis A, Holmes EC, Hotta H, Houghton M, Irwine B, Kohara M, Kolberg JA, Kuo G, Lau JYN, Lelie PN, Maertens G, McOmish F, Miyamura T, Mizokami M, Nomoto A, Prince AM, Reesink HW, Rice C, Roggendorf M, Schalm SW, Shikata T, Shimotohno K, Stuyver L, Trepo C, Weiner A, Yap PL, Urdea MS: A proposedsystem for the nomenclature of hepatitis C viral genotypes. Hepatology 19:1321-1324, 1994

    Google Scholar 

  18. Kato N, Yokosuka O, Hosoda K, Ito Y, Ohto M, Omata M:Quantification of hepatitis C virus by competitive reverse transcription-polymerase chain reaction: Increase of the virus inadvanced liver disease. Hepatology 18:16-20, 1993

    Google Scholar 

  19. Snedecar GW, Cochran WG: Statistical Methods. Ames, Iowa, Iowa State University Press, 1980

    Google Scholar 

  20. Hino K, Kondo T, Yasuda K, Fukuhara A, Fujioka S, Shimoda K, Niwa H, Iino S, Suzuki H: Pharmacokinetics and biological effects of beta interferon by intravenous (iv) bolus administration in healthy volunteers as compared with iv infusion. Jpn J Clin Pharmacol The r 19:625-635, 1988

    Google Scholar 

  21. Barouki FM, Witter FR, Griffin DE, Nadler PI, Woods A, Wood DL, Lietman PS: Time course of interferon levels, antiviral state, 29, 59-oligoadenylate synthetase and side effects in healthy men. J Interferon Res 7:29-39, 1987

    Google Scholar 

  22. Villa E, Trande P, Grottola A, Buttafoco P, Rebecchi AM, Stroffolini T, Callea F, Merighi A, Camellini L, Zoboli P, Cosenza R, Miglioli L, Loria P, Iori R, Carulli N, Manenti F:Alpha but not beta interferon is useful in chronic active hepatitis due to hepatitis C virus: A prospective, double-blind,randomized study. Dig Dis Sci 41:1241-1247, 1996

    Google Scholar 

  23. Pre z R, Pravia R, Artimez ML, Giganto F, Rodriguez M, Lombrana JL, Rodrigo L: Clinical efficacy of intramuscular human interferon-beta vs interferon-alpha 2b for the Treatment of chronic hepatitis C. J Viral Hepatitis 2:103-106, 1995

    Google Scholar 

  24. Saitoh H, Naitoh S, Okamoto H, Akahane Y: Prompt decrease Of circulating hepatitis C virus in patients with chronic hepatitis C after treatment with interferon. J Interferon Res 14:239-244,1994

    Google Scholar 

  25. Rubin LA, Kurman CC, Fritz ME, Biddison WE, Boutin B, Yarchoan R, Nelson DL: Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol 135:3172-3177, 1985

    Google Scholar 

  26. Hayashi J, Kishihara Y, Yamaji K, Yoshimura E, Ohmiya M, Tani Y, Ikematsu H, Kashiwagi S: Serum levels of soluble interleukin-2 receptors and effects of interferon-alpha for patients with chronic hepatitis C virus. Dig Dis Sci 40:1837-1841,1995

    Google Scholar 

  27. Castell JV, Gomez-Lechon MJ, David M, Hirano T, Kishimoto T, Heinrich PC: Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS 232:347-350, 1988

    Google Scholar 

  28. Kakumu S, Fukatsu A, Shinagawa T, Kurokawa S, Kusakabe A: Localisation of intrahepatic interleukin 6 in patients with acute and chronic liver disease. J Clin Pathol 45:408-411, 1992

    Google Scholar 

  29. Hashimoto H, Shibukawa N, Kojima Y: The mode of production of endotoxin-induced interferon in rabbit lymphoid cell cultures. II. Priming effect of interferon on apparently noninducible cells. MicrobiloImmunol 23:1033-1036, 1979

    Google Scholar 

  30. Satoh M, Shimada Y, Inagawa H, Minagawa H, Kajikawa T, Oshima H, Abe S, Yamazaki M, Mizuno D: Priming effect of interferons and interleukin 2 on endogenous production of tumor necrosis factor in mice. Jpn J Cancer Res 77:342-344,1986

    Google Scholar 

  31. Di Bisceglie AM, Conjeevaram HS, Fried MW, Sallie R, Park Y, Yurdaydin C, Swain M, Kleiner DE, Mahaney K, Hoofnagle JH: Ribavirin as Therapy for chronic hepatitis C. A randomized,double-blind, placebo-controlled trial. Ann Intern Med 123:897-903, 1995

    Google Scholar 

  32. Puoti C, Magrini A, Filippi T, Annovazzi G, Pannullo A:Effects of ursodeoxycholic acid on serum liver enzymes in patients with hepatitis C virus-related chronic liver disease. Eur J Gastroenterol Hepatol 7:151-154, 1995

    Google Scholar 

Download references

Authors
  1. Norihiro Furusyo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jun Hayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Misako Ohmiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yasunori Sawayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yasunobu Kawakami
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Iwao Ariyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Naoko Kinukawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Seizaburo Kashiwagi
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Furusyo, N., Hayashi, J., Ohmiya, M. et al. Differences Between Interferon-α and-β Treatment for Patients with Chronic Hepatitis C Virus Infection. Dig Dis Sci 44, 608–617 (1999). https://doi.org/10.1023/A:1026625928117

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1026625928117

Search

Navigation